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Abstract
Introduction: Motion of the prostate is problematic in the accurate delivery of
external beam radiation therapy (EBRT) for prostate cancer. This study
investigated the relationship between body mass index (BMI), an easily
measured indicator of obesity, and prostate motion. Methods: Prostate motion
during EBRT was assessed by measuring the displacement of fiducial markers
implanted within the prostate in 130 prostate cancer patients. Interfractional
motion was corrected on daily imaging through pre-treatment cone-beam-
computed tomography (CBCT) and intrafractional motion measured using
movie sequences captured using an electronic portal imaging device (EPID)
during treatment delivery. Results: There was no statistically significant
relationship between the mean intrafractional motion and BMI, except in the
left-right (LR) translation (P = 0.049) over the study population. For each BMI
category, there was no statistical significance (P > 0.05) between any of the
translations/rotations except LR (P = 0.003). Conclusion: While intrafractional
motion is an important consideration, prostate motion cannot be reliably
predicted through measurement of patient’s BMI.
Background
External beam radiation therapy (EBRT) is one of the
primary treatments options of prostate cancer.1 The
prostate is known to move within the pelvis due to
factors such as bladder and bowel filling. As such, daily
image-guided radiation therapy (IGRT) is
recommended.1,2
Obesity is an increasing global epidemic, with
implications in the treatment of prostate cancer. Obese
men have significantly greater chance of dying of prostate
cancer than non-obese men,3 and are approximately twice
as likely to develop a high-grade prostate cancer.4 Obesity
is associated with a 98% increase in prostate cancer risk,
after adjusting for lower prostate-specific antigen (PSA)
and a larger prostate size.5 In addition, overweight or obese
prostate cancer patients are more likely to be younger and
have co-morbidities such as hypertension and diabetes.6
Obesity limits the treatment options available to the
prostate cancer patient, with a higher Body Mass Index
(BMI) increasing the operative risk associated with a
radical prostatectomy.7 The most widely used non-
surgical treatment is radiation therapy. There is, however,
significantly greater set up variability in obese patients
compared to less obese patients when treating with
radiation therapy due largely to the variability in location
of external pelvic skin markers (used to set up the patient
on a daily basis) relative to internal anatomy.8
Overweight and obese patient groups show a significant
difference in interfractional prostate shift on a daily
basis.9
This study aimed to investigate the relationship
between obesity as measured by BMI and intrafractional
prostate displacement over the course of a radiation
therapy treatment.
Methods
The study was reviewed and approved by the institute’s
Human Research and Ethics Committee. A total of 130
patients of differing BMI were recruited and provided
written consent over a 3-year period (2011–2013). Of the
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176 prostate patients screened, 22 patients did not meet
eligibility criteria and 24 patients declined participation.
BMI was calculated using the World Health Organisation
(WHO) definition of the weight (kilograms) divided by
the square of the height (metres).10 Patients were then
categorised in the database according to the four major
WHO classifications (underweight, normal, overweight
and obese). Patients were excluded from the study if they
had previous or concurrent cancers within the pelvis, hip
prosthesis, ECOG performance status greater than 2, or if
dose constraints to critical structures were unachievable.
Dose constraints had to be met for inclusion in this study
so as not to negatively impact the clinician-graded side
effects and patient-reported quality of life, a secondary
analysis of this study not reported in this paper.
Patients had three gold seed fiducial markers (CIVCO,
Iowa, USA), 1 9 3 mm in size, inserted into the prostate
for IGRT. Patients were simulated according to
departmental protocol, positioned supine on the solid
carbon-fibre CT couch top, with a standard head rest, arms
on chest, kneefix under knees and footstocks supporting
feet and ankles. The standard departmental bowel and
bladder preparation protocol was adhered to, including an
empty rectum/bowel (achieved by taking Movicol laxative
everyday throughout treatment) and full bladder (achieved
by emptying their bladder then drinking 300 mL of water
20 min prior to their appointment).
Patients were planned on the XiO planning system
(Elekta CMS, Missouri, USA) according to departmental
protocols. A 3D conformal technique was used, with two
laterals (or posterior obliques), two anterior obliques and
a direct anterior beam. Treatment was delivered on the
department’s megavoltage (10 MV) linear accelerators.
Patients were queried each day as to their adherence to
the bladder and bowel protocol. If the patient reported
troubles, particularly in emptying their bowel that day,
alterations to the aperient schedule were considered.
Treatment times varied throughout the course of
treatment, between the hours of 8 am and 8 pm.
Imaging methods
The correction of interfractional prostate displacement was
performed by daily Cone Beam CT (CBCT) verification
imaging, matching to the fiducial markers. Bladder and
bowel volumes were assessed daily on the CBCT, and
corrective action taken by treatment staff if this varied
significantly from planned volume. Based upon the CBCT
match, the patient set up was corrected by shifting the
couch remotely. Movements were performed on any
parameter greater than 1 mm. The treatment couch could
only correct for the three translational displacements and
not rotational displacements, and so a ‘best-fit’ match was
performed by the treating radiation therapists where
rotation was observed. If the CBCT functionality was not
operational on a certain fraction, the patient’s set up was
verified and corrected utilising kV or MV matches,
requiring a manual adjustment of the couch with an action
level of 3 mm. These fractions were excluded from the
analysis. At the discretion of treatment staff, if significant
difference between bladder or rectum volume was
observed, the patient was taken off the treatment couch for
further remedial action prior to treatment delivery. This
was at the discretion of the treatment staff, with no set
protocols to measure significant differences.
Intrafractional motion was measured using movie loops
captured during the delivery of the anterior and lateral (or
posterior oblique) treatment fields using the iView
electronic portal imaging device (EPID) (Elekta,
Stockholm, Sweden). Images were acquired approximately
once every 5–10 sec during treatment delivery, allowing for
the measurement of any prostate movement during this
time. An average of 7–8 frames were acquired for each
lateral field, and 2–3 for the anterior field, however, this
was dependent upon each individual’s plan and treatment
delivery.
The principal investigator alone measured the
intrafractional motion on the movie captures to eliminate
inter-user variability. Intra-user variability was analysed
by measuring the intrafraction motion on eight sets of
images of four different patients (2 different images per
patient). The investigator was blinded to the patient’s
BMI during the measurement process to limit any bias in
measuring prostate motion. As the movie captures were
of the treatment fields, there could be some subjective
image quality differences noted between patients of
different sizes, however, the patient’s BMI was not
discernible from the quality of the movie capture image.
Where prostate rotation and/or deformation were visible,
the best fit was measured on the movie captures. This
was achieved aligning the FMs using the rotation feature
in iView (Fig. 1). Due to the planes analysed, pitch and
yaw could be measured, however, roll could not be
measured. As there was no rotational correction applied
at CBCT, the CBCT measured rotation was subtracted
from the movie capture rotation measurement, to
indicate the true intrafraction rotation. A correction for
gantry sag at the lateral and posterior oblique movie
capture angles was applied, whereby the measured gantry
sag (0.75–1.25 mm) at the appropriate angle was
subtracted from the measured data.
Statistical methods
Sample size was calculated to detect a displacement
difference of greater than 5 mm, for a level of
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significance of 0.05 and power of 80%. The overall
population mean and the mean intrafractional
displacements of each of the four BMI patient groups were
assessed for statistically significant difference utilising linear
regression analysis and analysis of variance (ANOVA).
While ANOVA determined if the BMI groups were
different, Tukey post hoc tests were then performed to
determine which groups were different, as the assumption
of homogeneity of variances was not violated. Frequency
and range data within 3 mm, 5 mm and 10 mm tolerances
were also assessed. All data were collected and analysed in
SPSS Version 19.0 software (IBM, Armonk, NY). Where
there were missing data for any of the components (CBCT




The mean BMI was 29.4 kg/m2 across the study cohort
(range of 18.22–47.00 kg/m2). As there was only one
underweight patient, the underweight and normal BMI
categories were combined for analysis. A total of 16
patients (12.3%) had less than three fiducial markers.
Further patient demographics are found in Table 1.
Across all patients, a total of 4357 out of 5038 fractions
(86.5%) had complete or partial movie capture data
collected. The number of fractions with missing movie
capture data across BMI categories are tabulated in
Table 1. Intra-user variability was measured at 0.44 mm,
0.38 mm and 0.73 degrees in the horizontal, vertical and
rotational planes respectively.
The mean and standard deviation for the overall
population in each intrafractional translation and rotation
is detailed in Table 2. Patient BMI could not significantly
predict mean intrafractional motion except for in left-
right (LR) translation (P = 0.049) through linear
regression analysis, as summarised in Table 3.
Further investigation into each of the BMI categories
was conducted. A one-way ANOVA was conducted to
determine if the mean prostate intrafraction motion
differed across the BMI categories. The mean and
standard deviations used in the ANOVA analysis are
presented in Table 2. There was no statistical significance
(P > 0.05) between any of the translations/rotations
across BMI categories except LR (P = 0.003), as
summarised in Table 4. Tukey HSD post hoc analysis
indicated that the LR difference from overweight to obese
(0.575, 95% CI (0.185–0.965)) was statistically significant
(P = 0.002). The plot for the LR intrafractional mean
motion is shown in Figure 2.
Figure 1. Example of rotation measure in iView.
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The frequency of the occurrence of displacement was
investigated by recording the percentage displacements
within 3 mm, 5 mm and 10 mm for translations, and 5,
10 and 20 degrees for rotations calculated by counting
the number of frames within each given margin. The
overall population results are summarised in Table 5,
with BMI category results displayed in Figure 3.
Discussion
Intrafraction motion
This study did not find any significant relationship
between patient BMI and intrafractional prostate motion
except in LR (P = 0.049), where the mean LR motion









LR (mm) 0.37  0.83 0.35  0.79 0.11  0.76 0.68  0.86
AP (mm) 0.34  1.48 0.31  1.51 0.19  1.59 0.49  1.38
SI (mm) 0.90  1.41 1.34  2.10 0.73  1.08 1.02  1.12
Pitch (deg) 0.84  3.57 1.55  3.83 1.16  3.97 0.08  2.83
Yaw (deg) 0.40  2.00 0.04  1.67 0.54  1.93 0.42  2.25
LR, left-right; AP, anterior-posterior; SI, superior-inferior.
Table 2. Intrafractional mean and standard












LR (mm) 0.032 0.024 0.029 0.0 to 0.057 3.945, P = 0.049
AP (mm) 0.033 0.025 0.049 0.001 to 0.098 4.155, P = 0.440
SI (mm) 0.000 0.008 0.007 0.038 to 0.052 0.050, P = 0.823
Pitch (deg) 0.17 0.009 0.087 0.035 to 0.21 1.992, P = 0.161
Yaw (deg) 0.000 0.009 0.003 0.069 to 0.076 0.009, P = 0.926
The bold indicates a significant result. LR, left-right; AP, anterior-posterior; SI, superior-inferior.
Table 3. Results for mean intrafractional
linear regression analysis.
Table 1. Patient characteristics.
Parameter Group
Total population
(Percentage) Underweight/Normal Overweight Obese
BMI Classification 130 Underweight: 1 (0.8%)
Normal: 24 (18.5%)
56 (43.1%) 49 (37.7%)
Dose (Gy) 78 109 (83.8%) 17 45 47
76 10 (7.7%) 2 7 1
74 11 (8.5%) 6 4 1
Seminal Vesicles Inclusion Entire course 34 (26.0%) 7 13 14
Partial course 73 (56.0%) 11 33 29
Not included 23 (18.0%) 6 11 6
Fiducial Markers 3 markers 114 (87.7%) 23 51 40
2 markers 14 (10.8%) 3 4 7
1 marker 2 (1.5%) 0 1 1
Number of Fractions
with missing movie capture data
681 (13.5%) 213 (4.2%) 232 (4.6%) 237 (4.7%)
Table 4. One way ANOVA for intrafractional translations rotation.
ANOVA
LR (mm) F(2, 130) = 6.126, P = 0.003
AP (mm) F(2, 130) = 0.743, P = 0.478
SI (mm) F(2, 130) = 2.045, P = 0.134
Pitch (deg) F(2, 130) = 1.646, P = 0.197
Yaw (deg) F(2, 130) = 0.487, P = 0.616
The bold indicates a significant result. LR, left-right; AP, anterior-
posterior; SI, superior-inferior.
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0.352  0.790 and 0.108  0.760 mm for underweight/
normal and overweight patients respectively.
The results indicated translational means and standard
deviations were within current planning target volume
(PTV) margins of 7–10 mm. While the mean
intrafractional motion is an important indicator of
motion, more extreme motions within a fraction, such as
sudden transient motion may not be reflected in the mean
or visualised in the movie captures. To investigate cases of
more extreme motion, both the range of motion, and the
frequency of displacement within 3, 5 and 10 mm were
analysed. Current departmental margins from clinical
target volume to PTV are 10 mm in LR, SI and anterior
directions, and 5–7 mm in the posterior direction.
Previous studies reducing the margins to as little as 3 mm
have been performed.11,12 When examining the overall
population in this study, the percentage of the
intrafractional motion within 3 mm was 83.4  17.0 and
81.6  16.0 for the SI and AP translations respectively.
This agrees closely with the findings of Nichol et al., where
motions of greater than 3 mm were observed in 12% of the
total measurements (every 9 sec over 9 min total time on
MRI scans).13
Two studies of note have investigated the correlation
between BMI and intrafraction prostate motion. Using
electromagnetic transponders, Butler et al., investigated
the effect of BMI on prostate displacement. Their overall
results based on 66 patients (mean BMI = 28.7  4.2 kg/
m2) show similar results.14 It should be noted that the
patients were treated in a prone position with a custom
thermoplastic hip-fix immobiliser over the buttocks and
abdomen. In separating the overall study population in to
low BMI (<30 kg/m2) and high BMI (≥30 kg/m2) groups,
no significant difference in the standard deviation of the
translational motions or vector was found.14
Our standard deviation findings are supported by those
of Thompson et al. Their conclusion was that while there
was no statistically significant difference in the
intrafraction between BMI categories, there may be
greater stability of the prostate in the larger BMI patients,
once isocentre correction has been made.15 Indeed, the
standard deviations of patients >35 kg/m2 were within
2 mm in all translational directions, however, it should
also be noted that there were only 8 patients in this sub-
group. Comparatively, our study had 21 patients with
BMIs >35 kg/m2 and we did not find this trend, except
for the LR direction.
Rotation
A standard deviation of 3.57 degrees for pitch reflects a
greater range in this rotation, a key finding of this study.
Rotation remains a challenge in the IGRT setting,
particularly in pitch which is influenced largely by rectal
volume differences. Bowel protocols minimise these rectal
differences, however, even if the patient has an acceptable
rectal diameter on planning scan, a small difference in
rectal diameter at treatment can produce a large
difference in prostate displacement and rotation. This was
further investigated by Oates et al., concluding that a
mean rectal diameter measured on daily CBCT of less
Table 5. Frequency of translations and rotations within given
margins, per fraction.
Overall population
Mean  SD (%) Min (%) Max (%)
LR
≤10 mm 100 100 100
≤5 mm 99.5  2.0 99 100
≤3 mm 95.9  7.0 62 100
AP
≤10 mm 99.5  2.0 89 100
≤5 mm 94.4  9.0 45 100
≤3 mm 81.6  16.0 27 100
SI
≤10 mm 99.6  2.0 78 100
≤5 mm 95.7  1.0 21 100
≤3 mm 83.4  17.0 12 100
Pitch
≤20 deg 99.1  2.6 81 100
≤10 deg 91.2  11.7 47 100
≤5 deg 69.4  22.4 13 100
Yaw
≤20 deg 100 100 100
≤10 deg 99  4.1 62 100
≤5 deg 91.8  14.7 39 100
LR, left-right; AP, anterior-posterior; SI, superior-inferior.
Figure 2. Intrafractional total mean left-right (LR) motion across body
mass index (BMI) categories.
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than or equal to 3.5 cm would result in a prostate
displacement of less than or equal to 5.5 mm.16
Rotation was evident in our results, particularly when
considering the magnitude and frequency of pitch
(Table 5 and Fig. 3). While IGRT strategies allow for ease
of translational corrections, there are currently limited
options for the correction of rotational displacements.
Current treatment couch tops with 6 degrees of freedom
capabilities allow for the correction of small rotations,
but not able to correct for larger rotations.
Pitch rotation is of particular concern if the seminal
vesicles (SVs) are within the PTV. As the prostate is
approximately spherical in shape, when treating prostate
only, rotational error has limited possibility of
Figure 3. Boxplots of frequencies for intrafractional translations and measured rotations.
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underdosing the PTV. However, the addition of SVs
within the PTV creates a much more irregularly shaped
PTV, increasing the possible clinical significance of
rotational errors. As 82% of this patient cohort included
SVs for part or all of their treatment course, this is an
important consideration. It was anecdotally noted that
differences in rectal filling at the prostate level affected
rotation and displacement. However, quantifying the
rectal distension and/or shape changes was beyond the
scope of this project.
Limitations
A major limitation of this study is that the movie capture
methodology does not provide real-time 3D data, with
only one aspect of the lateral or anterior treatment field
collected and measured at any given time. Thus,
movement in only two planes can be assessed for each
movie capture series, with the inability to reliably capture
large transient moves potentially occurring between fields
or frames. These transient moves are measured within the
literature, with Noel et al. detailing the risk of missing
motion with intermittent imaging techniques.17,18
Another limitation is the inability to measure prostate
deformation from the fiducial markers on the movie
captures. As such, the ‘best-fit’ match introduces
subjectivity, which was minimised through the
measurement of intrafraction motion by one investigator.
At present, there is no efficient method to measure prostate
deformation and this was therefore beyond the scope of
this project.
A small number of patients (n = 16, 12.3%) had only
1–2 fiducial markers present at time of treatment. The
rate of loss of markers was higher than expected as this
study was performed in conjunction with the
implementation of fiducial marker insertion within the
department, and thus represents the ‘learning curve’ for
the procedure. Of these 16 patients, the majority (n = 11,
68.8%) were within the first 40 patients recruited. In
these cases, the potentially less accurate measurement of
motion, particularly in rotations is recognised.19
The effect of bowel and bladder filling is well-known
as a contributory factor to intrafractional motion.20,21
Bladder and bowel filling protocols were adhered to in
this cohort, and if bladder and/or bowel was
significantly different on the pre-treatment CBCT,
corrective action would be undertaken by the treatment
staff at their discretion. The bladder volumes were not
investigated in this project, however, could be
retrospectively further analysed based on the pre-
treatment CBCTs. Rectal volumes have been analysed on
CBCT, and the effect on prostate intrafraction motion
described by Oates et al.16
Controversies in using BMI
The use of BMI as an indicator of obesity is contentious
within the health community, despite its wide use. One of
the main arguments against is the fact that a change in
weight, and therefore BMI, does not necessarily reflect a
change in obesity – particularly when exercise is proven to
increase skeletal muscle mass.22 Alternative measures
include waist circumference, hip-to-waist ratio, skin folds
or body fat composition,23,24 however, these may require
additional measurements or specialised equipment. The
advantage of BMI is that it is easily calculated from two
measurements, height and weight, standardly measured in
many health settings. This study included a validation of
the relationship of BMI and pelvic adiposity by measuring
pelvic adiposity on the planning CT (not reported in this
paper).25
Conclusion
Our findings did not support a relationship between
intrafractional motion and BMI. The linear regression
analysis did not find any statistically significant relationship
and thus BMI could not predict the intrafractional motion.
Our findings do support the ever-growing body of evidence
that highlights the importance of daily IGRT for the
treatment of prostate cancer, and the progression towards
intrafractional monitoring and correction. This is of
particular importance in the advancements of EBRT
treatments, including hypo-fractionated schedules.
Our rotational results indicate the importance of
correction for significant rotation, particularly pitch. The
higher standard deviation in pitch when compared with
the other rotations across the overall population is of note.
This remains a great challenge in the EBRT for prostate
cancer. These findings highlight the necessity for adherence
to bladder and bowel protocol, and for the development of
guidelines to inform the treatment therapists to take
decisive action should there be considerable bladder/
rectum volume changes on a daily basis.
In the continuing improvement of radiation therapy
for prostate cancer, IGRT must continue to play an
integral part. Advancements in the monitoring and
correction of intrafractional motion will allow for safer
dose escalation with the potential for reduced side effects,
and improved quality of life.
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